SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. “Chemobrain” in breast cancer? A prologue. Cancer. 2004; 101: 466475.
  • 2
    Meyers CA, Byrne KS, Komaki R. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer. 1995; 12: 231235.
  • 3
    Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002; 20: 485493.
  • 4
    Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biological mechanism? A cytokine-immunological model of cancer symptoms. Cancer. 2003; 97: 29192925.
  • 5
    Larson S, Dunn AJ. Behavioral effects of cytokines. Brain Behav Immunol. 2001; 15: 371387.
  • 6
    Valentine AD, Meyers CA, Kling MA, et al. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol. 1998; 25( Suppl 1): 3947.
  • 7
    Dantzer R, Bluthe RM, Kent S, et al. Behavioral effects of cytokines. In: RothwellNJ, DantzerRD, editors. Interleukin-1 in the brain. New York: Pergamon Press, 1992: 135150.
  • 8
    Plata-Salaman CR, French-Mullen JM. Interleukin-1 beta depresses calcium currents in CA1 hippocampal neurons at pathophysiological concentrations. Brain Res Bull. 1992; 29: 221223.
  • 9
    Ellison MD, Merchant RE. Appearance of cytokine-associated central nervous system myelin damage coincides temporally with serum tumor necrosis factor induction after recombinant interleukin-2 infusion in rats. J Neuroimmunol. 1991; 33: 245251.
  • 10
    Waage A, Espevik T. Interleukin-1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice. J Exp Med. 1988; 167: 19871992.
  • 11
    Wollman EE, Kopmels B, Bakalian A, et al. Cytokines and neuronal degeneration. In: RothwellNJ, DantzerRD, editors. Interleukin-1 in the brain. New York: Pergamon Press, 1992: 187203.
  • 12
    Huberman M, Sredni B, Stern L, et al. IL-2 and IL-6 secretion in dementia: correlation with type and severity of disease. J Neurol Sci. 1995; 130: 161164.
  • 13
    Sherman AM, Jaeckle K, Meyers CA. Pre-treatment cognitive performance predicts survival in patients with leptomeningeal disease. Cancer. 2002; 95: 13111366.
  • 14
    Meyers CA, Valentine AD. Neurological and psychiatric adverse effects of immunological therapy. CNS Drugs. 1995; 3: 5668.
  • 15
    Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour J, Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large cell lymphoma. Ann Intern Med. 1997; 127: 186194.
  • 16
    Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin's disease. Am J Med. 1997; 102: 2128.
  • 17
    Bruserud O, Nesthus I, Buhring HJ, Pawelec G. Cytokine modulation of interleukin 1 and tumour necrosis factor-alpha secretion from acute myelogenous leukaemia blast cells in vitro. Leuk Res. 1995; 19: 1522.
  • 18
    Kurzrock R, Wetzler M, Estrov Z, Talpaz M. Interleukin-1 and its inhibitors: a biologic and therapeutic model for the role of growth regulatory factors in leukemias. Cytokines Mol Ther. 1995; 1: 177184.
  • 19
    Sugiyama H, Inoue K, Ogawa H, et al. The expression of IL-6 and its related genes in acute leukemia. Leuk Lymphoma. 1996; 21: 4952.
  • 20
    Wechsler D. Wechsler Adult Intelligence Scale, 3rd edition. San Antonio: The Psychological Corp., 1997.
  • 21
    Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test—revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychologist. 1998; 12: 4355.
  • 22
    Benton AL, Hamsher KD. Multilingual aphasia examination. Iowa City: AJA Associates, 1989.
  • 23
    Lezak MD. Neuropsychological assessment, 3rd edition. New York: Oxford University Press, 1995.
  • 24
    Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999; 85: 11861196.
  • 25
    Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570579.
  • 26
    Wade DT. Measurement in neurological rehabilitation. New York: Oxford University Press, 1992.
  • 27
    Cohen J. Statistical power analysis for the behavioral sciences, 2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
  • 28
    Cummings JL. Subcortical dementia. New York: Oxford University Press, 1990.
  • 29
    Horuk R, Martin AW, Wang Z, et al. Expression of chemokine receptors by subsets of neurons in the central nervous system. J Immunol. 1997; 158: 28822990.
  • 30
    Meyers CA, Seabrooke LF, Albitar M, Estey EH. Association of cancer-related symptoms with physiological parameters: a case report [letter]. J Pain Symptom Manage. 2002; 24: 359361.